Now Reading
Novo Nordisk (CPH:NOVO.B) publishes 10th Integrated Annual Report
Novo Nordisk (CPH:NOVO.B) publishes 10th Integrated Annual Report
Published 02-04-14
Issued by Novo Nordisk
Summary
The report details the company's social, environmental and financial results for 2013
Report Highlights
On 3 February 2014, Novo Nordisk published its 2013 Annual Report detailing the company’s social, environmental and financial results for 2013. The report highlights the company’s progression towards long-term targets during a year of challenges and setbacks. Novo Nordisk has taken an integrated approach to reporting since 2004, accounting for social, environmental and financial performance.
In the 2013 report, Novo Nordisk looks at how external events and stakeholder expectations are shaping the pharmaceutical industry and the public health agenda. Articles in the report include the global rise in diabetes, public trust in the pharmaceutical industry and address the question of obesity as a disease.
Novo Nordisk’s 2013 social, environmental and financial performance highlights include:
Financial
- Increased sales by 12% in local currencies and by 7% in Danish kroner to DKK 83.6 billion
- Increased operating profit by 15% in local currencies and by 7% in Danish kroner to DKK 31.5 billion
- Increased net profit by 18% to DKK 25.2 billion
Social
- Reached an estimated 24.3 million people with diabetes care products during 2013, up from 22.8 million in 2012
- Created 3,700 new jobs in the company
- Increased employee engagement during high employee growth as measured in the annual company-wide survey on adherence to the Novo Nordisk Way
Environmental
- Increase in CO2 emissions from energy consumption of 2% compared to 2012
- Increase in water consumption of 8% compared to 2012
- Increase in energy consumption of 6% compared to 2012
Download the report
Novo Nordisk’s Annual Report 2013 is available as a downloadable PDF.
Novo Nordisk values feedback and welcomes questions or comments about its reporting and performance at annualreport@novonordisk.com.
For more information about Novo Nordisk’s sustainability, visit novonordisk.com/sustainability
require_once 'counter/results/hit.php'; //hits counter do not remove
?>
Novo Nordisk
Novo Nordisk
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. We believe that a healthy economy, environment and society are fundamental to long-term value creation. This is why we manage our business in accordance with the Triple Bottom Line business principle and consider the financial, environmental and social impact of our business decisions. The strategic commitment to corporate sustainability has brought the company onto centre stage as a leading player in today's business environment, recognised for its integrated reporting, stakeholder engagement and consistently high sustainability performance.